Table 6.
Univariate analysis of the relationship between clinicopathological features and epidermal growth factor receptor (EGFR), HER2 and KRAS gene mutations
| Variable | EGFR mutation | HER2 mutation | KRAS mutation | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | % | P‐value* | n | % | P‐value* | n | % | P‐value* | |
| Total (n = 349) | 102 | 29 | 6 | 1.7 | 21 | 6 | |||
| Sex | <0.0001 | NS (0.19) | NS (0.85) | ||||||
| Male (n = 226) | 35 | 15 | 2 | 0.9 | 14 | 6 | |||
| Female (n = 123) | 67 | 54 | 4 | 3.2 | 7 | 6 | |||
| Histology | <0.0001 | NS (0.18) | 0.0061 | ||||||
| Adenocarcinoma (n = 242) | 101 | 42 | 6 | 2.5 | 20 | 8 | |||
| Non‐adenocarcinoma (n = 107) | 1 | 1 | 0 | 0.0 | 1 | 1 | |||
| Smoking history † | <0.0001 | 0.037 | NS (0.14) | ||||||
| Never or light smoker ‡ (n = 131) | 71 | 54 | 5 | 3.8 | 4 | 3 | |||
| Heavy smoker (n = 201) | 29 | 14 | 1 | 0.5 | 15 | 7 | |||
| Undetermined (n = 17) | 2 | 12 | 0 | 0.0 | 2 | 12 | |||
| P‐stage † | 0.024 | NS (0.67) | NS (0.07) | ||||||
| I or II (n = 226) | 75 | 33 | 5 | 2.2 | 17 | 8 | |||
| III or IV (n = 97) | 20 | 21 | 1 | 1.0 | 2 | 2 | |||
| Undetermined (n = 26) | 7 | 27 | 0 | 0.0 | 2 | 8 | |||
†
Patients whose smoking history (n = 17) and P‐stage (n = 26) could not be determined were excluded from the analyses.
‡
Pack‐years < 20.
*
*Fisher's exact test. NS, not significant.